Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Eli Lilly

Pfizer

Weight-loss drugs are taking the U.S. by storm. JPMorgan Chase (NYSE: JPM ) is forecasting that the market for weight-loss medications could reach $100 billion in annual sales.

Pound for Pound: 3 Buzzworthy Drug Stocks Worth Their Weight in Gold

Scientists hope that a new class of treatments for alcohol use disorder, smoking and other addictive behaviors is on the horizon.

Ozempic, Wegovy may curb drinking, smoking and other addictive behaviors – here's what we know

Novo Nordisk's decision to launch its weight-loss drug Wegovy in Britain last week despite severe supply constraints may partly have been motivated by a desire to get ahead of rival Eli Lilly's own similar drug, industry sources said.

Analysis: Wegovy launch in UK may underline Novo's need to get ahead of Lilly

Novo Nordisk, the maker of the blockbuster obesity injection, has singlehandedly saved the country from a recession

Wegovy: the slimming drug that keeps Denmark's economy growing

As Novo Nordisk and Eli Lilly duke it out in the weight-loss drug market with Ozempic, Wegovy and Mounjaro, drug company competitors plan to join the fray.

Big pharma's blockbuster obesity drug battle is just getting started, and it's headed for $100 billion

UnitedHealth Group

UnitedHealth Group is a foundational piece of the healthcare system in America. Demand for Pfizer's Covid vaccine may have waned, but profits are going to good use.

3 Top Healthcare Stocks to Buy for September

The rise in obesity is having a massive impact on the global economy, according to Goldman Sachs. The bank estimates that obesity will drag down the world's GDP by $4 trillion in 2035.

The economic cost of obesity is expected to soar to $4 trillion by 2035. Weight loss drugs like Ozempic could change that, Goldman Sachs says.

Novo Nordisk is seeing unprecedented growth as demand surges for its diabetes and weight-loss treatments. Following its Q2 earnings release, the company announced a 2-for-1 stock split, which is set to occur shortly.

1 Stock Split Stock to Buy Hand Over Fist Right Now

Amazon

Planet Fitness

With the United States economy demonstrating strong performance recently, Federal Reserve officials are considering to double their 2023 growth projections. Economic data has consistently exceeded analysts' and economists' expectations, prompting the unofficial estimate from the Atlanta Federal Reserve to suggest a 5.6% annualized expansion in Q3 2023.

The 3 Best Stocks to Buy Now: September 2023

The JPMorgan Chase analyst team tracking the European pharmaceutical company boosted its price target. "Boosted" might be an understatement, as the figure was raised by 25%.

Why Novo Nordisk Stock Topped the Market on Thursday

Eli Lilly and Denmark's Novo Nordisk are expected to roughly split the market for weight-loss drugs, both as diabetes and obesity treatments.

Weight-Loss Drug Market Can Hit $100 Billion, J.P. Morgan Says.

As researchers work to test whether Novo Nordisk (NYSE:NVO)'s fat-busting drug Wegovy can also be used as a treatment for dementia and alcohol addiction, some analysts are pointing to a potential "paradigm shift" in the way obesity is treated.  Last week the Danish drugmaker, which is listed in Copenhagen and New York, briefly became Europe's largest company as investors continued to pile in following the initial data of its 'SELECT' trial of a once-weekly injection of Wegovy.

Wegovy drugmaker Novo Nordisk to make $70bn a year from weight-loss alone, as analysts await full SELECT trial data

Novo Nordisk is keen to replicate Ozempic's success. It just made two acquisitions that could lead to another big victory.

Novo Nordisk Is Already Working on Ozempic 2.0. Here's How to Profit

SoFi Technologies

Due to what could be an unsustainable rally for equities, you may be looking for Nasdaq stocks to sell now. We've had an incredible run this year, but there are some additional indiciations that our luck has come to an end.

3 Nasdaq Stocks to Sell in September Before They Crash & Burn

Novo Nordisk is now the biggest company in Europe with a valuation of more than $425 billion. The biotech company has taken over luxury goods maker LVMH in market cap size.

CHART OF THE DAY: Ozempic maker Novo Nordisk overtakes LVMH to become the biggest company in Europe

Novo Nordisk (NVO) announces the controlled and limited launch of Wegovy in the U.K. amid rising demand for weight loss treatment and supply constraints.

Novo Nordisk (NVO) Launches Wegovy in UK Amid Supply Issues

American depositary receipts of Novo Nordisk (NVO) climbed 1.5% in early trading on Tuesday after launching its popular weight-loss drug, Wegovy, in the U.K.

Novo Nordisk Becomes Europe's Most Valuable Company as Wegovy Launches in UK

Launch of weight-loss drug in UK helps Danish firm to market value of $428bn

Wegovy maker Novo Nordisk becomes Europe's most valuable firm

Novo Nordisk has dethroned Bernard Arnault's luxury goods giant LVMH as Europe's most valuable company.

The maker of Wegovy and Ozempic is now Europe's most valuable company

Novo Nordisk has been trading places with LVMH for the title of Europe's most valuable company. The Danish pharmaceutical giant makes the buzzy weight-loss drugs Wegovy and Ozempic.

Business is booming for the maker of weight-loss drugs Wegovy and Ozempic — so much so that it is threatening luxury giant LVMH's crown as Europe's most valuable firm

The pharma company's Wegovy medication helps it overtake luxury goods maker LVMH, with a market value of around $420 billion.

Novo Nordisk Is Now Europe's Biggest Company, Driven by Weight-Loss Drug. How Eli Lilly Could Benefit.

UK-based Simple Online Pharmacy has received stock of Novo Nordisk's weight-loss drug Wegovy, a company spokesperson said on Tuesday, one day after Novo launched the drug in Britain.

Wegovy supply from Novo Nordisk has arrived in UK, Simple Online Pharmacy says

Novo Nordisk A/S (NYSE: NVO) is in focus on Monday after it launched its weight loss drug in another European market – the United Kingdom. Novo Nordisk is facing supply constraints But the pharmaceutical behemoth did confirm that the weekly injection will initially be available via NHS only to a limited number of eligible patients.

Novo Nordisk rolls out its weight loss drug Wegovy in the U.K.

People in Britain who can afford to pay out of their own pocket may get easier access to Novo Nordisk's weight-loss drug Wegovy than those seeking treatment in the country's state-run health service, some doctors and medical experts warned on Monday.

Pent-up private Wegovy demand prompts UK availability concerns

Several prominent UK-based insurers including Aviva, Axa, and WPA will not cover the costs of the newly launched weight-loss drug, Wegovy, under their private medical insurance policies.  Since insurers typically cover acute conditions, which are characterised as diseases, illnesses, or injuries that are likely to respond quickly to treatment, the so-called “miracle” obesity drug developed by Novo Nordisk (NYSE:NVO) does not qualify.

News for Novo Nordisk Stock (NVO)